| Title |
Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies
|
|---|---|
| Published in |
Targeted Oncology, April 2018
|
| DOI | 10.1007/s11523-018-0561-6 |
| Pubmed ID | |
| Authors |
Pedro C. Barata, Dhrmesh Gopalakrishnan, Vadim S. Koshkin, Prateek Mendiratta, Matt Karafa, Kimberly Allman, Allison Martin, Jennifer Beach, Pam Profusek, Allison Tyler, Laura Wood, Moshe Ornstein, Timothy Gilligan, Brian I. Rini, Jorge A. Garcia, Petros Grivas |
| Abstract |
Little is known about the outcomes, safety, and response to subsequent therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab outside clinical trials. The objectives of the study include to report the clinical efficacy and safety of atezolizumab, and the response to future therapies in clinical practice outside clinical trials. This is a retrospective, single-center study including consecutive patients with confirmed mUC who received at least one dose of atezolizumab 1200 mg every 3 weeks between May 2016 and April 2017. Seventy-nine patients, median age 72 years (range 29-93), 71% men and 76% ECOG PS 0-1, were identified. Most patients (79%) had primary cancer in the bladder, 62% had prior surgery, and 75% received at least one prior line of treatment (34 patients had prior cisplatin-based chemotherapy). Best response included 18% partial response, 29% stable disease, and 53% progressive disease. Patients were on atezolizumab for a median of 2.7 months (95%CI, 1.8-3.6) and median PFS was 3.2 months (95%CI, 1.6-4.8). A total of 33 (42%) patients had significant (any cause) AEs, including grade 4 hyperbilirubinemia in two patients; no toxic deaths were reported. At time of data analysis, only 18% of patients received at least one subsequent line of treatment for a median of 1.8 months (95%CI, 0.0-5.0) while 42% were referred to palliative care/hospice or died. Patients with mUC who progressed on atezolizumab were unlikely to receive subsequent systemic treatments and the benefit of those treatments appeared limited in our cohort. The findings may impact timing and designs of clinical trials in mUC. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 60% |
| Spain | 1 | 10% |
| Brazil | 1 | 10% |
| Italy | 1 | 10% |
| Unknown | 1 | 10% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 4 | 40% |
| Members of the public | 4 | 40% |
| Science communicators (journalists, bloggers, editors) | 1 | 10% |
| Practitioners (doctors, other healthcare professionals) | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 17% |
| Student > Master | 3 | 13% |
| Other | 2 | 8% |
| Student > Bachelor | 2 | 8% |
| Unspecified | 1 | 4% |
| Other | 3 | 13% |
| Unknown | 9 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 25% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 13% |
| Nursing and Health Professions | 2 | 8% |
| Unspecified | 1 | 4% |
| Unknown | 12 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2018.
All research outputs
#6,221,521
of 24,775,802 outputs
Outputs from Targeted Oncology
#89
of 600 outputs
Outputs of similar age
#100,797
of 334,709 outputs
Outputs of similar age from Targeted Oncology
#5
of 14 outputs
Altmetric has tracked 24,775,802 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 600 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,709 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.